Trial Profile
Evaluation of symptom relief in functional dyspepsia patients with PPI-resistant Gastroesophageal reflux disease -Acotiamide + standard-dose PPI vs double-dose PPI ; Prospective multi-center randomized study-
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2018
Price :
$35
*
At a glance
- Drugs Acotiamide (Primary) ; Rabeprazole
- Indications Gastro-oesophageal reflux; Non-ulcer dyspepsia
- Focus Therapeutic Use
- 05 Jun 2018 Results presented at the Digestive Disease Week 2018
- 19 May 2016 Status changed from not yet recruiting to completed.
- 25 Jul 2014 New trial record